Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Cytosorbents ( (CTSO) ) has issued an announcement.
CytoSorbents Corporation announced the commencement of a rights offering, distributing non-transferable Subscription Right Warrants to stockholders and certain warrantholders. The offering, which allows the purchase of units comprising common stock and warrants at $1.00 per unit, aims to raise capital and potentially strengthen the company’s market position, with implications for shareholder value and operational expansion.
More about Cytosorbents
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery through blood purification. Their proprietary technology uses biocompatible polymer beads to remove toxic substances from blood, with applications in cardiothoracic surgery and critical illnesses. The company’s lead product, CytoSorb®, is approved in the European Union and distributed in 76 countries, with ongoing developments in the U.S. and Canada.
YTD Price Performance: -17.57%
Average Trading Volume: 128,566
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $50.17M
For an in-depth examination of CTSO stock, go to TipRanks’ Stock Analysis page.
